JSP191 for Myelodysplastic Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called JSP191 for individuals with myelodysplastic syndrome (MDS), specifically those with low-risk types experiencing symptoms such as frequent low blood cell counts. The main goal is to determine if JSP191 is safe and well-tolerated as a second-line therapy, used after other treatments have failed. Participants will receive varying doses of JSP191 to identify the optimal amount. Suitable candidates have MDS and symptoms like low blood counts. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new therapy.
Do I have to stop taking my current medications for the JSP191 trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.
Is there any evidence suggesting that JSP191 is likely to be safe for humans?
Research shows that JSP191 is generally safe for people. In earlier studies, 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) received JSP191 without experiencing serious side effects, suggesting it is well tolerated.
In another study, 17 patients with MDS or AML also took JSP191 and reported no severe side effects. These findings support the idea that JSP191 does not cause serious harm.
While these results are encouraging, it's important to remember that JSP191 remains in the early stages of testing. Although safety information is limited, current evidence suggests it is safe for people to use.12345Why do researchers think this study treatment might be promising?
Most treatments for Myelodysplastic Syndrome (MDS) involve chemotherapy or hypomethylating agents, which aim to control the disease and manage symptoms. However, JSP191 is unique because it targets CD117, a receptor on certain blood-forming stem cells, potentially clearing out abnormal cells more effectively. This novel mechanism could offer a more targeted approach compared to traditional therapies. Researchers are excited about JSP191 as it might provide a new avenue for treatment, especially for patients who don't respond well to existing options.
What evidence suggests that JSP191 might be an effective treatment for Myelodysplastic Syndrome?
Research has shown that JSP191, the investigational treatment in this trial, offers promising results for treating myelodysplastic syndrome (MDS). In a previous study, JSP191 helped all 17 participants produce healthy blood cells, indicating recovery. The treatment also reduced leftover cancer cells in 12 out of 15 participants. Additionally, JSP191 was well-tolerated, with no severe side effects reported. These early findings suggest that JSP191 could serve as an effective backup treatment for MDS.12356
Who Is on the Research Team?
Medical Director
Principal Investigator
Jasper Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults over 18 with low to intermediate-risk Myelodysplastic Syndrome (MDS) who have symptoms like anemia or bleeding. Women able to have children must use effective birth control, and men too, during the study and for 3 months after. Participants need to understand and agree to the study's requirements.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JSP191 on Day 1 of each 8-week cycle for 4 consecutive cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JSP191
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jasper Therapeutics, Inc.
Lead Sponsor